Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Pegcetacoplan Extension in C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis
jRCT2041260092Active, not recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Jul 2024
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of pegcetacoplan in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by Apellis Pharmaceuticals. Started Jul 2024; status: active, not recruiting.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on jRCT2041260092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260092.